Rhumbline Advisers Sells 3,069 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Rhumbline Advisers trimmed its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 4.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,822 shares of the medical instruments supplier's stock after selling 3,069 shares during the period. Rhumbline Advisers owned approximately 0.26% of ICU Medical worth $9,001,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Harvest Fund Management Co. Ltd purchased a new position in ICU Medical in the fourth quarter worth $33,000. Quarry LP boosted its stake in shares of ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 214 shares during the period. Murphy & Mullick Capital Management Corp purchased a new position in ICU Medical during the 4th quarter valued at about $52,000. Venturi Wealth Management LLC increased its position in ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock valued at $82,000 after buying an additional 206 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in ICU Medical by 88.8% in the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 300 shares during the period. 96.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ICUI has been the subject of several analyst reports. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James decreased their target price on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research report on Friday, May 9th. Finally, KeyCorp reduced their price objective on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, ICU Medical presently has a consensus rating of "Buy" and an average price target of $192.67.

ICU Medical Trading Down 2.1%

ICU Medical stock traded down $2.77 during midday trading on Thursday, hitting $131.68. 19,397 shares of the stock were exchanged, compared to its average volume of 276,228. The company has a fifty day simple moving average of $136.57 and a two-hundred day simple moving average of $149.09. ICU Medical, Inc. has a 52 week low of $111.24 and a 52 week high of $196.26. The stock has a market capitalization of $3.24 billion, a PE ratio of -28.81 and a beta of 0.88. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, topping the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The company had revenue of $599.49 million for the quarter, compared to analysts' expectations of $574.15 million. During the same period last year, the firm earned $0.96 earnings per share. The business's revenue for the quarter was up 6.7% on a year-over-year basis. Equities research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Christian B. Voigtlander sold 4,985 shares of the stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total transaction of $640,572.50. Following the transaction, the chief operating officer now directly owns 6,088 shares in the company, valued at approximately $782,308. This represents a 45.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ben Sousa sold 2,000 shares of ICU Medical stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the transaction, the insider now owns 479 shares in the company, valued at approximately $65,795.44. The trade was a 80.68% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,097 shares of company stock worth $4,860,156 over the last 90 days. Corporate insiders own 1.50% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.